How does it feel to watch a billion dollars in revenue circle the drain? Just ask Roche executives; their blockbuster Avastin got the thumbs-down as a breast cancer treatment at yesterday’s FDA advisory panel meeting. And if the agency follows that expert advice, the drug could lose up to…

According to pharmaceutical and healthcare market research company Manhattan Research, U.S. nurses believe they considerably influence patients’ health decisions and behavior.

Original Source of U.S. Nurses Believe They Considerably Influence Patient Health Decisions and Behavior

It’s a good news, bad news kind of day for pharma sales. The good news–in the U.K., some experts think that a proposed overhaul of the National Health Service could mean more jobs for sales reps and their more technical brethren, health managers. That’s because the new NHS would…

Good news for Merck’s ( NYSE: MRK ) HIV drug franchise. The company’s Isentress drug fought off the virus as well as older drugs did, when used as start-up therapy in combination with Abbott Laboratories’ ( NYSE: ABT ) Kaletra treatment. It’s the sort of research that could affect…

Johnson & Johnson ( NYSE: JNJ ) says it’s been subpoenaed by a federal grand jury and is cooperating in an investigation into the series of high-profile recalls of its consumer drugs. And it’s facing other legal actions stemming from those recalls, including lawsuits against its McNeil Consumer Healthcare…

Novartis delivered a strong performance in the second quarter of 2010 – with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines – as the Group made progress on its agenda on innovation, growth and productivity.

Original Source of Novartis delivers strong financial performance…

Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People’s Liberation Army General Hospital (301 Hospital) in Beijing, China.

Original Source of Bayer Schering Pharma enters strategic partnership with Hospital in China

Who’s the Big Kahuna of HIV drugs? If you said GlaxoSmithKline ( NYSE: GSK ) or Abbott Laboratories ( NYSE: ABT ), you’re wrong. It’s Gilead Sciences ( NASDAQ: GILD ), at least according to sales figures compiled by Reuters . Gilead drugs occupy the top two slots in…

Two generics makers have received some bad news from court. Teva Pharmaceutical Industries ( NASDAQ: TEVA )

It’s Day 2 after the Avandia vote, and the fallout continues.